10-K/A: AEON Biopharma Files Amended Annual Report to Include Omitted Exhibits

Sentiment:

Annual Report Amendment 12 August 2024 4:15 PM

AEON Biopharma has filed an amendment to its annual report to include exhibits that were inadvertently omitted in the original filing.

Summary

AEON Biopharma filed an amendment to its annual report on Form 10-K/A for the fiscal year ended December 31, 2023.
This amendment, the second such filing, is solely to include exhibits that were unintentionally left out of the original filing on March 29, 2024, and the first amendment on May 14, 2024.
The amendment does not change or update any other information from the original filing and does not reflect any events after the original filing date.
The company's Class A common stock is registered under Section 12 of the Securities Exchange Act of 1934 and is listed on the NYSE American under the symbol AEON.
As of August 7, 2024, there were 39,522,238 shares of Class A common stock outstanding.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, with no significant positive or negative news. The need for an amendment suggests a minor issue, but overall the sentiment is neutral.

Positives

The company is taking steps to ensure all required information is available to investors by filing this amendment.
The company has a clear structure with Class A common stock listed on the NYSE American.

Negatives

The need for a second amendment indicates a potential oversight in the initial filing process.
The company had to restate previous financial statements due to error corrections.

Risks

The company's certificate of incorporation includes provisions that could delay or prevent a change of control.
The company's board has the power to issue preferred stock which could dilute the voting power of common stockholders.
The exclusive forum provision in the certificate of incorporation may limit stockholders' ability to litigate disputes in a favorable forum.
The company is subject to Section 203 of the DGCL, which could prevent certain business combinations.

Management Comments

Marc Forth, the Chief Executive Officer, certified that the report does not contain any untrue statements of material fact.

Industry Context

This filing is a standard regulatory requirement for publicly traded companies and does not indicate any specific industry trends or competitive pressures.

Comparison to Industry Standards

The company's corporate governance structure, including the staggered board and anti-takeover provisions, is common among publicly traded companies.
The use of Delaware law for incorporation and the exclusive forum provision are also standard practices.
The company's share structure with Class A common stock and authorized preferred stock is typical for a company of its size and stage.

Stakeholder Impact

The filing ensures that shareholders have access to all required information.
The anti-takeover provisions may impact shareholders by potentially limiting their ability to influence company control.

Key Dates

Date	Description
December 12, 2022	Date of the Business Combination Agreement.
February 8, 2021	Date of the Warrant Agreement between Priveterra Acquisition Corp. and Continental Stock Transfer & Trust Company.
January 30, 2020	Date of the Consulting Agreement between AEON Biopharma, Inc. and Eric Carter, M.D.
June 21, 2021	Date of the Settlement and License Agreement between AEON Biopharma, Inc. and Medytox, Inc.
July 29, 2022	Date of the Amendment to License and Supply Agreement between Daewoong Pharmaceutical Co., LTD. and AEON Biopharma, Inc.
December 20, 2019	Date of the License and Supply Agreement between Daewoong Pharmaceutical Co., LTD. and AEON Biopharma, Inc.
January 8, 2023	Date of the Second Amendment to the License and Supply Agreement between AEON Biopharma, Inc. and Daewoong Pharmaceutical Co., Ltd.
April 24, 2023	Date of the Third Amendment to License and Supply Agreement between Daewoong Pharmaceutical Co.
April 27, 2023	Date of Amendment No. 1 to Business Combination Agreement.
July 21, 2023	Date of the Amended and Restated Registration Rights Agreement.
March 18, 2024	Date of the Termination Agreements with ACM ARRT J LLC and Polar Multi-Strategy Fund.
March 19, 2024	Date of the Subscription Agreement, Security Agreement, and Guaranty with Daewoong Pharmaceutical Co., LTD.
March 19, 2024	Date of the Fourth Amendment to License and Supply Agreement between AEON Biopharma, Inc. and Daewoong Pharmaceutical Co., LTD.
March 29, 2024	Date of the original filing of the Annual Report on Form 10-K.
May 14, 2024	Date of the first amendment to the Annual Report on Form 10-K/A.
August 7, 2024	Date of the share count.
August 12, 2024	Date of this Amendment No. 2 to the Annual Report on Form 10-K/A.

Keywords

amendment, annual report, exhibits, Form 10-K/A, common stock, AEON Biopharma, securities, NYSE American, corporate governance, Delaware General Corporation Law

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.